These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8217350)

  • 1. Proliferation markers in breast cancer.
    Silvestrini R
    Eur J Cancer; 1993; 29A(11):1501-2. PubMed ID: 8217350
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunohistochemical quantification of steroid receptors and other prognosis factors in human breast cancer patients.
    Fritz P; Tuczek HV; Offinger B; Schwarzmann P; Schieszl S; Wu X; Kleine B; Blödorn J; Multhaupt H
    Prog Histochem Cytochem; 1992; 26(1-4):146-58. PubMed ID: 1283015
    [No Abstract]   [Full Text] [Related]  

  • 3. Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance.
    Dowsett M; Makris A; Ellis P; Johnston SR; Salter J; Detre S; Humphries S; Saccani-Jotti G; Powles TJ; Smith IE
    Ann N Y Acad Sci; 1996 Apr; 784():403-11. PubMed ID: 8651589
    [No Abstract]   [Full Text] [Related]  

  • 4. Receptor status, proliferating activity, and c-erbB2 oncoprotein. An immunocytochemical evaluation in breast cancer.
    Campani D; Sarnelli R; Fontanini G; Martini L; Cecchetti D; De Luca F; Squartini F
    Ann N Y Acad Sci; 1993 Nov; 698():167-73. PubMed ID: 7904137
    [No Abstract]   [Full Text] [Related]  

  • 5. Proliferation index as a prognostic marker in breast cancer.
    Veronese SM; Gambacorta M; Gottardi O; Scanzi F; Ferrari M; Lampertico P
    Cancer; 1993 Jun; 71(12):3926-31. PubMed ID: 8508358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic significance of the S-phase and MIB1 (Ki-67) proliferation parameters in node-negative breast carcinoma].
    Harbeck N; Dettmar P; Thomssen Ch; Pache L; Ziffer P; Fizi K; Jänicke F; Nathrath W; Schmitt M; Graeff H
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():142-7. PubMed ID: 8672914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring proliferation in routine fine needle aspirates. Immunocytochemical detection of bromodeoxyuridine incorporation and Ki-67 expression in breast aspirates.
    Buley ID; Morrison EH; Kaklamanis L; Horak E; Gatter KC
    Cytopathology; 1992; 3(3):149-54. PubMed ID: 1511119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of different methods for determination of proliferative activity of breast carcinomas].
    Mink D; Villena-Heinsen C; Tossounidis I; Schmidt W
    Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():53-6. PubMed ID: 8672927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the evaluation of proliferative activity predict malignancy of prognosis in endocrine tumors?
    DeLellis RA
    Hum Pathol; 1995 Feb; 26(2):131-4. PubMed ID: 7860041
    [No Abstract]   [Full Text] [Related]  

  • 10. Ki-67 reactivity in breast carcinoma analyzed by a computer-assisted image system: preliminary results.
    Mir R; Johnson H; Mathur R; Wise L; Kahn LB
    J Natl Med Assoc; 1995 Aug; 87(8):554-9. PubMed ID: 7674345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proliferation markers in gliomas: a comparison of BUDR, KI-67, and MIB-1.
    Davis RL; Onda K; Shubuya M; Lamborn K; Hoshino T
    J Neurooncol; 1995; 24(1):9-12. PubMed ID: 8523082
    [No Abstract]   [Full Text] [Related]  

  • 12. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences.
    Gaglia P; Bernardi A; Venesio T; Caldarola B; Lauro D; Cappa AP; Calderini P; Liscia DS
    Eur J Cancer; 1993; 29A(11):1509-13. PubMed ID: 8217353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ki 67 growth fraction in carcinomas and benign lesions of the breast].
    Kunz J; Schmidt A
    Zentralbl Pathol; 1993 Aug; 139(3):201-5. PubMed ID: 8218121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Correlation with clinical outcome.
    Delahunt B; Bethwaite PB; Thornton A; Ribas JL
    Cancer; 1995 Jun; 75(11):2714-9. PubMed ID: 7743475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer.
    Veronese SM; Maisano C; Scibilia J
    Anticancer Res; 1995; 15(6B):2717-22. PubMed ID: 8669852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers.
    Gee JM; Douglas-Jones A; Hepburn P; Sharma AK; McClelland RA; Ellis IO; Nicholson RI
    J Pathol; 1995 Nov; 177(3):285-93. PubMed ID: 8551391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Breast carcinoma: evaluation of hormone receptors and pS2, erb-B2, P-glycoprotein and Ki-67 markers].
    Abadjian G; Antoun R
    J Med Liban; 1996; 44(1):10-5. PubMed ID: 8965315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-S1, a novel proliferative marker: flow cytometric assessment of staining in human breast carcinoma cells.
    Camplejohn RS; Brock A; Barnes DM; Gillett C; Raikundalia B; Kreipe H; Parwaresch MR
    Br J Cancer; 1993 Apr; 67(4):657-62. PubMed ID: 7682430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle kinetic effects of tamoxifen on human breast cancer cells. Flow cytometric analyses of DNA content, BrdU labeling, Ki-67, PCNA, and statin expression.
    Danova M; Pellicciari C; Zibera C; Mangiarotti R; Gibelli N; Giordano M; Wang E; Mazzini G; Riccardi A
    Ann N Y Acad Sci; 1993 Nov; 698():174-81. PubMed ID: 7904138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating and tissue markers in the longitudinal management of breast cancer patients.
    Schwartz MK
    Adv Exp Med Biol; 1994; 353():47-53. PubMed ID: 7985541
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.